Business Context and Reporting Period
This Form 8-K was filed by Dyadic International, Inc. on June 18, 2026. The filing addresses a critical corporate governance event: the receipt of a notification from The Nasdaq Stock Market LLC regarding potential delisting of the Company's common stock (trading symbol: DYAI).
Key Financial Metrics and Listing Status
The filing does not provide specific revenue, profit, cash flow, or debt figures for the current period. However, it discloses the following financial conditions triggering the delisting notice:
- Bid Price: The Company failed to maintain the minimum bid price of $1.00 per share required by Nasdaq Listing Rule 5450(a)(1).
- Shareholders' Equity: As of June 17, 2026, the Company did not meet the $5 million shareholders' equity requirement necessary to qualify for a compliance extension.
- Continued Listing Standards: The Company failed to meet any of the following minimum conditions under Nasdaq Listing Rule 5550(b):
- $2.5 million in shareholders' equity.
- $35 million in market value of listed securities.
- $500,000 of net income from continuing operations.
Material Changes and Delisting Proceedings
On June 18, 2026, Nasdaq initiated a process that could result in the delisting of Dyadic's securities. This action follows the expiration of a 180-day compliance period (ending June 17, 2026) during which the Company failed to regain compliance with the Bid Price Rule. Additionally, the Company failed to meet the Continued Listing Standards, which initially had a deadline of September 23, 2026, but now serve as an additional basis for delisting due to the Bid Price deficiency.
Outlook, Management Commentary, and Risks
Management Action: The Company plans to request a hearing before an independent Nasdaq hearings panel. This request automatically stays any suspension or delisting action until the panel's written decision. The Company may seek an extension to regain compliance, with the maximum potential deadline extending to December 15, 2026.
Outlook and Uncertainty: There is no assurance that the Company will regain compliance, that the panel will grant an extension, or that delisting will be avoided. An adverse decision may be appealed to the Nasdaq Listing and Hearing Review Council.
Risks and Contingencies:
- Liquidity and Capital: Delisting could adversely affect stock liquidity and market price, as well as the Company's ability to obtain additional capital to fund operations and continue as a going concern.
- Operational Risks: The filing references a history of net losses, reliance on third parties, capital needs, and the success of clinical trials and microbial protein production platforms as key risk factors.
Investor Verification Checklist
- Verify the current market price of DYAI to assess the severity of the bid price deficiency.
- Review the Company's most recent Form 10-K (filed March 25, 2026) for detailed financial statements regarding shareholders' equity and net income.
- Monitor the status of the hearing request with the Nasdaq hearings panel and the scheduled hearing date.
- Assess the Company's capital raising plans to determine if they can meet the $5 million equity requirement for an extension.
- Check for any subsequent filings regarding the outcome of the Nasdaq panel decision or appeals.